Business
Curis Provides First Quarter 2023 Business Update
Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry
About this update from Curis, Inc.
[{"type":"text","content":"Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3\nCuris strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer\nStrong balance sheet with $71.8 million in cash and investments; cash runway into 2025\nManagement to host conference call today at 4:30 p.m. ET\nLEXINGTON, Mass., May 4, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the first quarter ended March 31, 2023.\n\n \n \n \n \n \n \n\n \n\"I am pleased with our progress in the TakeAim leukemia study. We enrolled the additional patients requested by FDA ahead of schedule in the first quarter – which is indicative of both the clear unmet need in leukemia and the excitement among the clinical community for this novel agent. We are on track to collect data from these patients in the second quarter and discuss these data with the FDA in the third quarter of this year. I am also pleased to announce the expansion of the Curis Executive Team with the addition of Jonathan Zung, Ph.D. as our Chief Development Officer. Dr. Zung is a well-respected leader in the industry and brings a wealth of experience from senior roles across the industry, most recently at Evelo. We look forward to his contributions toward our mission at Curis,\" said James Dentzer, President and CEO of Curis.\n\"I am excited to be joining the Curis team during this critical time, as the company advances its first-in-class IRAK4 inhibitor, emavusertib. In biotech, it is rare to find a novel target with such broad therapeutic potential in that exciting period between the initial demonstration of clear single agent activity and the final stage of clinical development. I look forward to working with the Curis team on the clinical development of emavusertib and helping to establish it as a cornerstone therapy in hematologic malignancies,\" said Dr. Zung.\nFirst Quarter 2023 and Recent Operational Highlights\nAppointed new CDO \nDr. Zung was appointed as Chief Development Officer of Curis on May 1, 2023. Prior to joining Curis, he served as CDO of Evelo Biosciences, where he was responsible for the operational design and execution of Evelo's clinical progr...